secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xilio Therapeutics, Inc. (XLO)
CIK:        0001840233
Form:       8-K
Filed at:   2025-08-28T23:59:59+00:00
Accession:  0001558370-25-011802
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Xilio Therapeutics receives second Nasdaq deficiency letter for low stockholders' equity; bid price also non-compliant
--------------------------------------------------------------------------------

- Reported stockholders' equity of $7.069M as of June 30, 2025, below $10M minimum required for Nasdaq Global Select Market.
- Company has 45 days (until Oct 6, 2025) to submit a compliance plan; Nasdaq may grant up to 180-day extension.
- Also remains out of compliance with $1.00 minimum bid price requirement, initial cure period expires Oct 1, 2025.
- No immediate effect on listing; company may also seek transfer to Nasdaq Capital Market.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840233/000155837025011802/0001558370-25-011802-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840233/000155837025011802/xlo-20250822x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-011802

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer